Evgen Pharma Share Discussion Threads

[riggerbeautz] 17/2/2021 07:26

MM to your credit you guessed right, these boards are all about opinions.

[bumpa33] 17/2/2021 07:22

nice one Evgen, good progress - well done mm on the early assessment. The ‘experts’; got that one wrong too.

[moneymunch] 17/2/2021 07:20

Lol HH, I'm not clever enough to work for Evgen unlike some other self-proclaimed experts, but I did get a lot of grief elsewhere and accused of misinformation for the reasonable speculation that Evgen could report early interim results on efficacy...but guess what...it looks like Evgen will report early. Gl...On and UP!!! :-)

[hodhasharon] 17/2/2021 07:14

I'm sure MM works for EVG. He is freakishly accurate with his predictions.

If his target is 300p for EVG I'm holding.

[amaretto1] 17/2/2021 07:13

Good result .... all on course !!

[moneymunch] 17/2/2021 07:10

Early reporting very likely, who would have thought???? Ho ho ho Gla ;-)

In addition to the DSMB safety and futility assessment, Dundee University ("the Sponsor") has decided to review the top-level unblinded data in a preliminary assessment of possible efficacy. This may lead to adjustments to the design of the trial for remaining patients, including in patient numbers, and possibly early termination for either safety, futility or alternatively, strong efficacy.

[hodhasharon] 17/2/2021 07:10

Looks good to me.

[moneymunch] 17/2/2021 07:05

Update on patient recruitment

EVGEN PHARMA PLC

Released 07:00:10 17 February 2021

RNS Number : 3128P

Evgen Pharma PLC

17 February 2021

 

            Evgen Pharma plc

 ("Evgen" or the "Company")

 

Update on patient recruitment

STAR COVID-19 trial exceeds 100 patients

 

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces that as of 16 February, a total of 102 patients had been recruited and randomised to the STAR trial ("SFX-01 Treatment for Acute Respiratory infections").

 

This Phase II/III trial is a randomised, placebo-controlled trial, sponsored by the University of Dundee and funded by the UK charity LifeArc. It is investigating whether the Company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome ("ARDS") in patients with suspected COVID-19. Patients may be included in the study if they are infected with SARS-CoV-2 or another respiratory infections causing community-acquired pneumonia.

 

The trial design includes an assessment of safety and futility by a Data Safety and Monitoring Board ("DSMB") who will review unblinded data on the first 100 patients treated. In addition to the DSMB safety and futility assessment, Dundee University ("the Sponsor") has decided to review the top-level unblinded data in a preliminary assessment of possible efficacy. This may lead to adjustments to the design of the trial for remaining patients, including in patient numbers, and possibly early termination for either safety, futility or alternatively, strong efficacy. It is expected that this initial data will be available during the second quarter of calendar 2021.

 

The Sponsor has also requested that the DSMB review data from the first 60 patients solely for safety and this process will be starting shortly. The outcome of this is expected to be available in early Q2 2021.

 

Completion of recruitment to the STAR trial is anticipated at the end of 2021/Q1 2022, assuming there are no substantial changes in the total patients to be recruited. 

 

Dr Huw Jones, CEO of Evgen, commented: "We are pleased with the recruitment progress in this trial and would again like to thank Professor James Chalmers and his colleagues at Dundee for their considerable efforts in a very challenging clinical environment. Randomising over 100 patients is an important milestone in this trial and takes us a step closer to receiving the initial data from the study. We look forward to further updating the market as we progress through this important trial.''

[pugugly] 16/2/2021 21:08

amaretto1 - re 7265 - Message received - Having problem with applications for the open offer - I take it that it is your open offer application you are referring to? As no trades marked at 8p.

[dennisbergkamp] 16/2/2021 20:27

Clicked Nobby. Do you need to approve?

ta,
D

[amaretto1] 16/2/2021 19:29

Take them all with you ... sooner the better for me ....Just got another 85k at 8 pence..,They asked me if i want more ...Not sure yet, talking to Company Thursday :-)

[nobbygnome] 16/2/2021 18:08

You now have coins so need to click on the Guild threads and apply to join.

[moneymunch] 16/2/2021 15:04

Yes indeed bocker, and so looking forward to the publication of the Scientific Paper along with the compelling data that's excited Huw so much, which hopefully will attract significant interest, if the same excitement is conveyed to the market. Gl :-)


Dr Huw Jones, Evgen CEO, commented: "We are excited by this compelling new data in a type of cancer which has severely limited therapeutic options for the patient. The positive tolerability profile of SFX-01 makes it a viable option for use in addition to current treatments. Our plan is to expand upon these pre-clinical data in this and new collaborations, and start the process of designing an appropriate Phase II clinical trial."

[mr greedy1] 16/2/2021 15:00

Hi Nobby

Could I please have a coin for EVG and SNG.

Many thanks

[bocker01] 16/2/2021 14:50

Should be interesting to see how Prof Claudio Festuccia's involvement unfolds. And some news on patent filings....

[moneymunch] 16/2/2021 13:45

The following is the latest research from Prof Claudio Festuccia Università degli Studi Dell'Aquila Italy, who has recently been appointed to Evgen's Scientific Advisory Board, and no doubt the main man involved in Evgen's Glioblastoma target imho. Gla :-)

Project

Glioblastoma in vivo

December 2020

Abstract and Figures

Background: The probability of local tumor control after radiotherapy (RT) remains still miserably poor in pediatric rhabdomyosarcoma (RMS). Thus, understanding the molecular mechanisms responsible of tumor relapse is essential to identify personalized RT-based strategies. Contrary to what has been done so far, a correct characterization of cellular radioresistance should be performed comparing radioresistant and radiosensitive cells with the same isogenic background. Methods: Clinically relevant radioresistant (RR) embryonal (RD) and alveolar (RH30) RMS cell lines have been developed by irradiating them with clinical-like hypo-fractionated schedule. RMS-RR cells were compared to parental isogenic counterpart (RMS-PR) and studied following the radiobiological concept of the "6Rs", which stand for repair, redistribution, repopulation, reoxygenation, intrinsic radioresistance and radio-immuno-biology. Results: RMS-RR cell lines, characterized by a more aggressive and in vitro pro-metastatic phenotype, showed a higher ability to i) detoxify from reactive oxygen species; ii) repair DNA damage by differently activating non-homologous end joining and homologous recombination pathways; iii) counteract RT-induced G2/M cell cycle arrest by re-starting growth and repopulating after irradiation; iv) express cancer stem-like profile. Bioinformatic analyses, performed to assess the role of 41 cytokines after RT exposure and their network interactions, suggested TGF-β, MIF, CCL2, CXCL5, CXCL8 and CXCL12 as master regulators of cancer immune escape in RMS tumors. Conclusions: These results suggest that RMS could sustain intrinsic and acquire radioresistance by different mechanisms and indicate potential targets for future combined radiosensitizing strategies.

[jakman59] 16/2/2021 12:26

Please can I have a coin Nobby to join the Guild

[nojjer41] 16/2/2021 09:33

Nobby, could I have a coin to join the EVG Guild please? Many thanks.

[beergut] 16/2/2021 08:53

Evgen has just popped on to my radar, and looking to gather information before deciding to take a position.

Can I have access to the Evgen Guild please.


Thanks,